Physician profile
Kellie Ford
NPI 1063898617
$967.47
in general payments reported to CMS, 2019-2025
19 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.65 · 2022: $19.67 · 2023: $63.64 · 2024: $312 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $889.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $889.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $235.37 | 2024-2025 | Ozempic, Wegovy |
| Amgen INC. | $136.74 | 2024 | Repatha |
| Novartis Pharmaceuticals Corporation | $111.36 | 2025 | |
| Lilly USA, LLC | $90.09 | 2024-2025 | Zepbound |
| Mdd US Operations, LLC | $50.06 | 2023 | Gocovri |
| Astrazeneca Pharmaceuticals LP | $47.05 | 2024-2025 | Wainua |
| Alnylam Pharmaceuticals INC. | $37.58 | 2024-2025 | Amvuttra |
| Kiniksa Pharmaceuticals International, Plc | $33.30 | 2024 | Arcalyst |
| Adamas Pharmaceuticals, INC. | $27.94 | 2021 | |
| Ionis Pharmaceuticals, INC. | $24.60 | 2025 | Tryngolza |
| Abbott Laboratories | $24.56 | 2024 | Cardiomems |
| Chiesi USA, INC. | $23.57 | 2025 | Juxtapid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.05 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $22.36 | 2025 | Nexletol, Nexlizet |
| Abbvie INC. | $19.67 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $18.43 | 2021 | |
| Impulse Dynamics (USA) INC. | $15.88 | 2024 | Optimizer |
| Avion Pharmaceuticals | $13.58 | 2023 | Dhivy |
| Kyowa Kirin, INC. | $12.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kellie Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.